BioNotebook: Big bets in life science venture capital; Chimerix stock offering; IPOs and dealmaking abound
This article was originally published in Scrip
Coherus raises $55m, Nurix gets $25.1m as VC funding balloons; New IPO filings despite recent price-cutting; Chimerix offering grosses $103.8m; Sarepta buys manufacturing facility; and Ventrus/Assembly merge.
You may also be interested in...
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.